540 related articles for article (PubMed ID: 25979243)
1. Transurethral resection of the prostate for patients with Gleason score 6 prostate cancer and symptomatic prostatic enlargement: a risk-adaptive strategy for the era of active surveillance.
Koo KC; Park SU; Rha KH; Hong SJ; Yang SC; Hong CH; Chung BH
Jpn J Clin Oncol; 2015 Aug; 45(8):785-90. PubMed ID: 25979243
[TBL] [Abstract][Full Text] [Related]
2. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
[TBL] [Abstract][Full Text] [Related]
3. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
4. Pathologic findings in patients who underwent robot-assisted radical prostatectomy following active surveillance: a prospective study in a single center.
Ha YS; Yu J; Patel N; Hassanzadeh Salmasi A; Parihar J; Kwon TG; Kim WJ; Kim IY
Minerva Urol Nefrol; 2015 Mar; 67(1):1-9. PubMed ID: 25664959
[TBL] [Abstract][Full Text] [Related]
5. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
[TBL] [Abstract][Full Text] [Related]
6. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
[TBL] [Abstract][Full Text] [Related]
7. Active surveillance in Canadian men with low-grade prostate cancer.
Cristea O; Lavallée LT; Montroy J; Stokl A; Cnossen S; Mallick R; Fergusson D; Momoli F; Cagiannos I; Morash C; Breau RH
CMAJ; 2016 May; 188(8):E141-E147. PubMed ID: 26927971
[TBL] [Abstract][Full Text] [Related]
8. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
[TBL] [Abstract][Full Text] [Related]
9. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
[TBL] [Abstract][Full Text] [Related]
10. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
11. Low prostate-specific antigen and no Gleason score upgrade despite more extensive cancer during active surveillance predicts insignificant prostate cancer at radical prostatectomy.
Han JS; Toll AD; Amin A; Carter HB; Landis P; Lee S; Epstein JI
Urology; 2012 Oct; 80(4):883-8. PubMed ID: 22921697
[TBL] [Abstract][Full Text] [Related]
12. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
14. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
15. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance.
Berglund RK; Masterson TA; Vora KC; Eggener SE; Eastham JA; Guillonneau BD
J Urol; 2008 Nov; 180(5):1964-7; discussion 1967-8. PubMed ID: 18801515
[TBL] [Abstract][Full Text] [Related]
16. Pathological Outcome following Radical Prostatectomy in Men with Prostate Specific Antigen Greater than 10 ng/ml and Histologically Favorable Risk Prostate Cancer.
Yu J; Kwon YS; Kim S; Han CS; Farber N; Kim J; Byun SS; Kim WJ; Jeon SS; Kim IY
J Urol; 2016 May; 195(5):1464-1470. PubMed ID: 26608903
[TBL] [Abstract][Full Text] [Related]
17. Pathological outcomes in men with prostate cancer who are eligible for active surveillance.
Wang SC; Chen CC; Yang CK; Hung SW; Jan YJ; Ou YC
J Chin Med Assoc; 2018 Apr; 81(4):348-351. PubMed ID: 28988599
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
[TBL] [Abstract][Full Text] [Related]
19. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
20. Surgical outcomes for men undergoing laparoscopic radical prostatectomy after transurethral resection of the prostate.
Jaffe J; Stakhovsky O; Cathelineau X; Barret E; Vallancien G; Rozet F
J Urol; 2007 Aug; 178(2):483-7; discussion 487. PubMed ID: 17561162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
